Press coverage about Corvus Pharmaceuticals (NASDAQ:CRVS) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.5865877457983 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

A number of brokerages have recently issued reports on CRVS. Zacks Investment Research raised Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Tuesday, November 7th. Credit Suisse Group raised Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 price target on the stock in a research report on Wednesday, August 23rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $20.25.

Shares of Corvus Pharmaceuticals (CRVS) traded up $0.50 during mid-day trading on Tuesday, hitting $9.80. The stock had a trading volume of 117,800 shares, compared to its average volume of 108,052. Corvus Pharmaceuticals has a 1-year low of $8.27 and a 1-year high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. equities research analysts anticipate that Corvus Pharmaceuticals will post -2.82 EPS for the current year.

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 10,000 shares of Corvus Pharmaceuticals stock in a transaction dated Monday, November 20th. The shares were acquired at an average cost of $10.79 per share, with a total value of $107,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 46.40% of the company’s stock.

WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Insider Buying and Selling by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with's FREE daily email newsletter.